SurvivorshipNCT07165600
Yoga to Improve Disparities in Cancer Survivorship
A study testing Yoga in people with Survivorship and Cancer, run by University of California, San Francisco at 1 site in United States.
Trial summary
This clinical trial tests the impact of a racially concordant trainer led yoga program on quality of life and symptom burden in Black and/or African American cancer survivors. Black individuals in the United States are more affected by cancer, despite modern advances. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Survivorship, Cancer
- What is being tested?
- Yoga
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Sep 2025to 31 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age >=18 years.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
- Diagnosed with any malignancy and/or received any cancer directed therapy within 5 years of enrollment.
- Be able to speak, read and write in English.
- Self-identify as Black or African American race.
- Reside in California.
Who cannot join
- Contraindication to any study-related procedure or assessment.
- Participants complete the PAR-Q at screening to ensure that they are physically well enough to enroll in the study. If they report any conditions that may be contraindications to physical activity, physician clearance will be required prior to enrollment.
- Planned major surgery during the study period.
- Any major injuries that limit physical activity.
- Active or radiographic evidence of cancer requiring treatment during the study period. Adjuvant therapy is allowed (including hormonal, immuno-, or targeted therapy). Ongoing treatment such as hormone or maintenance therapies including HER2 directed, or immunotherapy are only allowed if patient has no evidence of disease on most recent imaging.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California, San Francisco
San Francisco, California, 94143
About this study
This clinical trial tests the impact of a racially concordant trainer led yoga program on quality of life and symptom burden in Black and/or African American cancer survivors. Black individuals in the United States are more affected by cancer, despite modern advances. Cancer treatments can impact physical and mental health and overall quality of life and Black individuals report worse physical function and quality of life and less access to culturally appropriate support services. Yoga has been shown to have a positive impact on cancer and cancer treatment related symptoms and quality of life, however, a one size fits all approach has not been shown to be effective in diverse populations. A trainer that shares the same racial or ethnic background as the participant (racially concordant) may have a positive impact on communication, trust, and may improve accessibility and participation. Participating in a yoga program led by a racially concordant trainer may improve quality of life and symptom burden in Black and/or African American cancer survivors.
Read the detailed description
PRIMARY OBJECTIVE:
- Determine the feasibility and acceptability of a yoga intervention among Black individuals with cancer.
SECONDARY OBJECTIVES:
- To estimate the effect of the intervention on health-related quality of life.
II. To estimate the effect of the intervention on symptom burden. III. To determine the safety of the intervention.
OUTLINE:
Participants engage in racially concordant trainer led yoga sessions over 60 minutes once weekly (QW) on weeks 1-4 then participate in self-practice video led yoga sessions over 10-15 minutes on weeks 5-8.
After completion of study intervention, patients are followed up at 3 months.
- Conditions
- Survivorship, Cancer
- Being tested
- Yoga
- Keywords
- Cultural support services
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
YogaOther
Also called Yoga training, Yoga sessions
Physical activity
| Study group | Role | What they receive |
|---|---|---|
| Yoga Intervention | Experimental | Participants receive a 4-week yoga intervention consisting of weekly 60-minute yoga sessions led by a trained facilitator. Participants may also participate remotely. At the end of the program, participants will also receive access to online yoga training videos (created by the study team) to continue self-practice. Receives: Other: Yoga |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall completion rate
The completion rate is defined as the proportion of enrolled individuals who attend at least 2 yoga sessions.
Measured: Up to 8 weeks
Median score on the Feasibility of Intervention Measure (FIM)
The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
Measured: Up to 8 weeks
Median score on the Acceptability of Intervention Measure (AIM)
The AIM is a four-item measure of implementation that assesses participants perceived acceptability of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
Measured: Up to 8 weeks
Median score on the Intervention Appropriateness Measure (IAM)
The IAM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
Measured: Up to 8 weeks
Secondary outcomes (2)
Change in scores on the Patient Reported Outcomes Measurement Information System (PROMIS®-29) (Version 2) score
The PROMIS 29 v2.0 profile assesses pain intensity using a response scale for each item ranging from 0 (no pain) to 10 (worst imaginable pain) on seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance), with four items per domain and one question which addresses pain intensity item. PROMIS-29 domains are scored using a T-score metric, with higher scores indicate higher levels of functioning.
Measured: Up to 8 weeks
Percentage of participants reporting adverse events
The effect of the intervention on symptom burden will be evaluated by participants self-reporting of adverse events. Adverse events will be classified and graded according to the Common Terminology Criteria for Adverse Events (CTCAEv 5).
Measured: Up to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2025
- Study start24 Sep 2025
- Primary completion31 May 2026
- Study completion31 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SurvivorshipStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sorbarikor Piawah, MD, MPH, Principal investigator, University of California, San FranciscoChloe Atreya, MD, PhD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07165600
- Sponsor's protocol ID
- 25802
- Other IDs
- NCI-2025-05225
- Status last verified
- Jun 2026
- First submitted
- 3 Sep 2025
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Yoga to Improve Disparities in Cancer Survivorship
- ClinicalTrials.gov ID
- NCT07165600
- Acronym / sponsor ID
- 25802
- Conditions
- Survivorship, Cancer
- Keywords
- Cultural support services
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 24 Sep 2025 (actual)
- Primary completion
- 31 May 2026 (actual)
- Study completion
- 31 May 2026 (actual)
- First posted
- 10 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial tests the impact of a racially concordant trainer led yoga program on quality of life and symptom burden in Black and/or African American cancer survivors. Black individuals in the United States are more affected by cancer, despite modern advances. Cancer treatments can impact physical and mental health and overall quality of life and Black individuals report worse physical function and quality of life and less access to culturally appropriate support services. Yoga has been shown to have a positive impact on cancer and cancer treatment related symptoms and quality of life, however, a one size fits all approach has not been shown to be effective in diverse populations. A trainer that shares the same racial or ethnic background as the participant (racially concordant) may have a positive impact on communication, trust, and may improve accessibility and participation. Participating in a yoga program led by a racially concordant trainer may improve quality of life and symptom burden in Black and/or African American cancer survivors.
Detailed description
PRIMARY OBJECTIVE:
- Determine the feasibility and acceptability of a yoga intervention among Black individuals with cancer.
SECONDARY OBJECTIVES:
- To estimate the effect of the intervention on health-related quality of life.
II. To estimate the effect of the intervention on symptom burden. III. To determine the safety of the intervention.
OUTLINE:
Participants engage in racially concordant trainer led yoga sessions over 60 minutes once weekly (QW) on weeks 1-4 then participate in self-practice video led yoga sessions over 10-15 minutes on weeks 5-8.
After completion of study intervention, patients are followed up at 3 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Yoga Intervention | Experimental | Other: YogaParticipants receive a 4-week yoga intervention consisting of weekly 60-minute yoga sessions led by a trained facilitator. Participants may also participate remotely. At the end of the program, participants will also receive access to online yoga training videos (created by the study team) to continue self-practice. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age >=18 years.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
- Diagnosed with any malignancy and/or received any cancer directed therapy within 5 years of enrollment.
- Be able to speak, read and write in English.
Key exclusion criteria (5 listed)
- Contraindication to any study-related procedure or assessment.
- Planned major surgery during the study period.
- Any major injuries that limit physical activity.
- Active or radiographic evidence of cancer requiring treatment during the study period. Adjuvant therapy is allowed (including hormonal, immuno-, or targeted therapy). Ongoing treatment such as hormone or maintenance therapies including HER2 directed, or immunotherapy are only allowed if patient has no evidence of disease on most recent imaging.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| YogaAlso: Yoga training, Yoga sessionsPhysical activity | Other | Yoga Intervention |
Primary outcome
Overall completion rate
Time frame: Up to 8 weeks
The completion rate is defined as the proportion of enrolled individuals who attend at least 2 yoga sessions.
Median score on the Feasibility of Intervention Measure (FIM)
Time frame: Up to 8 weeks
The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
Median score on the Acceptability of Intervention Measure (AIM)
Time frame: Up to 8 weeks
The AIM is a four-item measure of implementation that assesses participants perceived acceptability of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
Median score on the Intervention Appropriateness Measure (IAM)
Time frame: Up to 8 weeks
The IAM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is >= 4.
2 secondary outcomes
Change in scores on the Patient Reported Outcomes Measurement Information System (PROMIS®-29) (Version 2) score
Time frame: Up to 8 weeks
Percentage of participants reporting adverse events
Time frame: Up to 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Survivorship
Recruiting
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
Cancer, Survivorship
Not yet recruiting
Patient-reported Outcomes-driven Supportive Care Navigation Among Hispanic/Latinx Cancer Patients
Cancer
Active, not recruitingObservational study
A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sorbarikor Piawah, MD, MPH principal investigator
University of California, San Francisco
Chloe Atreya, MD, PhD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Yoga in people with Survivorship and Cancer, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall completion rate (time frame: Up to 8 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.